TR199902956T2 - Pozisyonlar 5 ve 6 i�inde de�i�tirilmi� olan GnRH antagonistleri. - Google Patents

Pozisyonlar 5 ve 6 i�inde de�i�tirilmi� olan GnRH antagonistleri.

Info

Publication number
TR199902956T2
TR199902956T2 TR1999/02956T TR9902956T TR199902956T2 TR 199902956 T2 TR199902956 T2 TR 199902956T2 TR 1999/02956 T TR1999/02956 T TR 1999/02956T TR 9902956 T TR9902956 T TR 9902956T TR 199902956 T2 TR199902956 T2 TR 199902956T2
Authority
TR
Turkey
Prior art keywords
switched
positions
gnrh antagonists
term
gnrh
Prior art date
Application number
TR1999/02956T
Other languages
English (en)
Turkish (tr)
Inventor
Semple Graeme
Jiang Guangcheng
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199902956(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of TR199902956T2 publication Critical patent/TR199902956T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR1999/02956T 1997-04-11 1998-04-13 Pozisyonlar 5 ve 6 i�inde de�i�tirilmi� olan GnRH antagonistleri. TR199902956T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists

Publications (1)

Publication Number Publication Date
TR199902956T2 true TR199902956T2 (xx) 2000-08-21

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02956T TR199902956T2 (xx) 1997-04-11 1998-04-13 Pozisyonlar 5 ve 6 i�inde de�i�tirilmi� olan GnRH antagonistleri.

Country Status (36)

Country Link
US (2) US5925730A (cg-RX-API-DMAC10.html)
EP (1) EP1003774B1 (cg-RX-API-DMAC10.html)
JP (2) JP4249806B2 (cg-RX-API-DMAC10.html)
KR (1) KR100519421B1 (cg-RX-API-DMAC10.html)
CN (1) CN1230442C (cg-RX-API-DMAC10.html)
AR (1) AR011217A1 (cg-RX-API-DMAC10.html)
AT (1) ATE319736T1 (cg-RX-API-DMAC10.html)
AU (1) AU728642B2 (cg-RX-API-DMAC10.html)
BR (1) BR9808523B1 (cg-RX-API-DMAC10.html)
CA (1) CA2286190C (cg-RX-API-DMAC10.html)
CY (2) CY1108063T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ299097B6 (cg-RX-API-DMAC10.html)
DE (2) DE122009000033I2 (cg-RX-API-DMAC10.html)
DK (1) DK1003774T3 (cg-RX-API-DMAC10.html)
EE (1) EE03974B1 (cg-RX-API-DMAC10.html)
ES (1) ES2260833T3 (cg-RX-API-DMAC10.html)
FR (1) FR09C0028I2 (cg-RX-API-DMAC10.html)
HR (1) HRP980197B1 (cg-RX-API-DMAC10.html)
HU (1) HU224836B1 (cg-RX-API-DMAC10.html)
IL (1) IL132303A0 (cg-RX-API-DMAC10.html)
LU (1) LU91585I2 (cg-RX-API-DMAC10.html)
MY (1) MY114811A (cg-RX-API-DMAC10.html)
NL (1) NL300395I2 (cg-RX-API-DMAC10.html)
NO (2) NO324991B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ500142A (cg-RX-API-DMAC10.html)
PL (1) PL194509B1 (cg-RX-API-DMAC10.html)
PT (1) PT1003774E (cg-RX-API-DMAC10.html)
RU (1) RU2199549C2 (cg-RX-API-DMAC10.html)
SI (1) SI1003774T1 (cg-RX-API-DMAC10.html)
SK (1) SK285381B6 (cg-RX-API-DMAC10.html)
TR (1) TR199902956T2 (cg-RX-API-DMAC10.html)
TW (1) TW505658B (cg-RX-API-DMAC10.html)
UA (1) UA58547C2 (cg-RX-API-DMAC10.html)
UY (1) UY24958A1 (cg-RX-API-DMAC10.html)
WO (1) WO1998046634A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA983062B (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) * 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
WO2005046707A1 (en) 2003-11-10 2005-05-26 Fein Seymour H Pharmaceutical compositions including low dosages of desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
EP2421887B1 (en) * 2009-04-24 2015-04-22 Polypeptide Laboratories A/S Method for the manufacture of degarelix
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
CA2822442C (en) 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
KR102140982B1 (ko) 2012-06-01 2020-08-05 훼링 비.브이. 데가렐릭스의 제조 방법
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
ES2885869T3 (es) * 2015-12-17 2021-12-15 Fresenius Kabi Ipsum S R L Procedimiento para la fabricación de degarelix y sus productos intermedios
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
WO2021018105A1 (en) 2019-07-29 2021-02-04 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
EP4656241A2 (en) 2021-11-01 2025-12-03 Shandong Luye Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist, and preparation method therefor and use thereof
WO2026068660A1 (en) 2024-09-26 2026-04-02 Ferring B.V. Lipidated gonadotropin releasing hormone analogues

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ATE144538T1 (de) * 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
CA2136079A1 (en) * 1992-12-18 1994-07-07 Fortuna Haviv Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
RU2084458C1 (ru) * 1993-05-27 1997-07-20 Институт высокомолекулярных соединений РАН Декапептид, обладающий противоопухолевой активностью
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
EP1003774B1 (en) 2006-03-08
BR9808523A (pt) 2000-05-23
CY2009008I2 (el) 2012-01-25
NO324991B1 (no) 2008-01-14
HRP980197A2 (en) 1999-02-28
WO1998046634A1 (en) 1998-10-22
SK285381B6 (sk) 2006-12-07
HUP0002704A3 (en) 2003-08-28
JP2005120101A (ja) 2005-05-12
AU728642B2 (en) 2001-01-11
NO994906L (no) 1999-12-13
NL300395I1 (nl) 2009-09-01
NL300395I2 (nl) 2010-01-04
KR20010006233A (ko) 2001-01-26
CZ358699A3 (cs) 2000-06-14
EE9900479A (et) 2000-06-15
JP4249806B2 (ja) 2009-04-08
AU6969898A (en) 1998-11-11
JP3645255B1 (ja) 2005-05-11
DE69833751D1 (de) 2006-05-04
NO2009016I2 (no) 2014-08-25
LU91585I2 (fr) 2009-09-17
CZ299097B6 (cs) 2008-04-23
CA2286190A1 (en) 1998-10-22
HUP0002704A2 (hu) 2000-12-28
IL132303A0 (en) 2001-03-19
NO2009016I1 (no) 2009-08-10
JP2001523229A (ja) 2001-11-20
MY114811A (en) 2003-01-31
NZ500142A (en) 2001-10-26
US5925730A (en) 1999-07-20
HK1025104A1 (en) 2000-11-03
FR09C0028I2 (fr) 2010-06-11
RU2199549C2 (ru) 2003-02-27
SI1003774T1 (sl) 2006-08-31
ES2260833T3 (es) 2006-11-01
SK139699A3 (en) 2000-11-07
CY1108063T1 (el) 2012-01-25
AR011217A1 (es) 2000-08-02
ATE319736T1 (de) 2006-03-15
DE122009000033I1 (de) 2009-09-17
HU224836B1 (en) 2006-03-28
DE122009000033I2 (de) 2011-07-21
CN1230442C (zh) 2005-12-07
CA2286190C (en) 2007-01-09
DE69833751T2 (de) 2006-11-09
HRP980197B1 (en) 2002-08-31
CN1259959A (zh) 2000-07-12
PL336213A1 (en) 2000-06-05
TW505658B (en) 2002-10-11
DK1003774T3 (da) 2006-07-03
CY2009008I1 (el) 2012-01-25
UA58547C2 (uk) 2003-08-15
BR9808523B1 (pt) 2010-02-09
PL194509B1 (pl) 2007-06-29
KR100519421B1 (ko) 2005-10-06
FR09C0028I1 (cg-RX-API-DMAC10.html) 2009-09-25
PT1003774E (pt) 2006-05-31
UY24958A1 (es) 2001-03-16
EP1003774A1 (en) 2000-05-31
ZA983062B (en) 1998-10-20
US6214798B1 (en) 2001-04-10
EE03974B1 (et) 2003-02-17
NO994906D0 (no) 1999-10-08

Similar Documents

Publication Publication Date Title
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
FI970810A0 (fi) Ionipolymeerejä sisältäviä biologisesti aktiivisia anioneja
DE59906975D1 (de) Wässrige reaktive spachtelmassen (i)
DE69936444D1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
NO982729D0 (no) Antagonister av det gonadotropinfrigj°rende hormon
ATE233735T1 (de) Neue phenanthridine
TR200000015T2 (tr) Bileşikler ve metodlar
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
DE69922822D1 (de) Rekombinante haarbehandlungsmittel
WO2001085196A3 (en) Cxcr4 antagonist treatment of hematopoietic cells
RU2001104349A (ru) Композиции и способы для терапии и диагностики рака предстательной железы
TR200100054T2 (tr) Paroksetin metansülfonat
MX9708401A (es) Genes reguladores de la cromatina.
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
YU13301A (sh) Muskarinski agonisti i antagonisti
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
TR200102041T2 (tr) Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions